⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL28432523 | 0.97 | — | — | |
| SCHEMBL22750752 | 0.74 | — | — | |
| SCHEMBL19322304 | 0.73 | — | — | |
| SCHEMBL18232965 | 0.73 | NOTUM (0.32) | — | |
| SCHEMBL14746911 | 0.72 | NOTUM (0.31) | — | |
| SCHEMBL19755675 | 0.66 | KDM4E (0.43) | — | |
| SCHEMBL30449 | 0.63 | — | — | |
| SCHEMBL12906161 | 0.61 | NOTUM (0.59) | — | |
| SCHEMBL9332908 | 0.58 | — | — | |
| SCHEMBL682543 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219954-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC | 2023-07-13 | — | — | US | claimed |
| US-11685736-B2 | P2X3 and/or P2X2/3 compounds and methods | ABS DEVELOPMENT 1, INC. (US) | 2023-06-27 | — | — | US | claimed |
| EP-3083619-B1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES LLC (US) | 2021-11-03 | — | — | EP | claimed |
| US-20200109143-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ABS DEVELOPMENT 1, INC. | 2020-04-09 | — | — | US | claimed |
| US-10544145-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2020-01-28 | — | — | US | claimed |
| US-20190248789-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ABS DEVELOPMENT 1, INC. | 2019-08-15 | — | — | US | claimed |
| US-20180186793-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ABS DEVELOPMENT 1, INC. | 2018-07-05 | — | — | US | claimed |
| US-20160318927-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC (US) | 2016-11-03 | — | — | US | claimed |
| WO-2023230609-A1 | HETEROCYCLIC PAD4 INHIBITORS | CELGENE CORPORATION (US) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023220435-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023196975-A1 | COMPOUNDS THAT INTERACT WITH RAS SUPERFAMILY PROTEINS FOR TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, LLC (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230219954-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC | 2023-07-13 | — | — | US | disclosed |
| US-11685736-B2 | P2X3 and/or P2X2/3 compounds and methods | ABS DEVELOPMENT 1, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| EP-4198024-A1 | PYRAZOLE MAGL INHIBITORS | H. Lundbeck A/S (DK) | 2023-06-21 | — | — | EP | disclosed |
| US-7169795-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| WO-2007005838-A2 | HCV INHIBITORS | VIROBAY, INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-02-02 | — | — | US | disclosed |
| WO-2005048922-A2 | SULFONYLAMINOVALEROLACTAMS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
| CN-1042910-A | The allylamine derivatives that replaces, their production method and application thereof | BANYU PHARMA CO LTD (JP) | 1990-06-13 | — | — | CN | disclosed |